Infarct size limitation: Acute N-acetylcysteine defense (ISLAND trial): Preliminary analysis and report after the first 30 patients

Clinical Cardiology

Volumn 19, Issue 2, 1996, Pages 94-100

  Šochman, Jan ^a   Vrbská, Jana ^a   Musilová, Blanka ^a   Roček, Miroslav ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

infarct size; myocardial infarction; N acetylcysteine; thrombolysis

Indexed keywords

ACETYLCYSTEINE; HEXOPRENALINE; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ECHOCARDIOGRAPHY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029795838     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960190205     Document Type: Article

References (28)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343, 311-322 (1994)
2. Bourassa MG, Alderman EL, Bertrand M, de la Fuente L, Gratsianski A, Kaltenbach M, King SB, Nobuyoshi M, Romaniuk P, Ryan TJ, Serruys PW, Smith HC, Sousa JE, Böthig S, Rapaport E: Report of the joint ISFC/WHO task force on coronary angioplasty. Circulation 78, 780-789 (1988)
3. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL: ACC/AHA task force report. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 12, 529-545 (1988)
4. Gunnar RM, Bourdillon PDV, Dixon DW, Fuster V, Karp RB, Kennedy JW, Klocke FJ, Passamani ER, Pitt B, Rapaport E, Reeves TJ, Russell RO, Sobel BE, Winters WL: ACC/AHA task force report. Guidelines for early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for early management of patients with acute myocardial infarction). J Am Coll Cardiol 16, 249-292 (1990)
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet ii, 349-360 (1988)
6. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet i, 397-401 (1986)
7. Sochman J, Kolc J, Vrána M, Fabián J: Cardioprotective effects of N-acetylcysteine: The reduction in the extent of infarction and occurrence of reperfusion arrhythmias in the dog. Int J Cardiol 28, 191-196 (1990)
8. Šochman J: Regional ischaemic and reperfusion injury, free oxygen radicals and the possible role of N-acetylcysteine in acute myocardial infarction. Cor Vasa 36, 269-279 (1994)
9. Sochman J, Kolc J, Vrána M: Cardioprotective effects of N-acetylcysteine(abstr). J Heart Failure 1, 396 (1993)
10. Sochman J, Peregrin JH: Total recovery of left ventricular function after acute myocardial infarction: Comprehensive therapy with streptokinase, N-acetylcysteine and percutaneous transluminal coronary angioplasty. Int J Cardiol 35, 116-118 (1992)
11. Ideker RE, Wagner GS, Ruth WK, Alonso DR, Bishop SP, Bloor CM, Fallon JT, Gottlieb GJ, Hackel DB, Phillips HR, Reimer KA, Roark SF, Rogers WJ, Savage RM, White RD, Selvester RH: Evaluation of a QRS scoring system for estimating myocardial infarct size II. Correlation with quantitative anatomic findings for anterior infarcts. Am J Cardiol 49, 1604-1614 (1982)
12. Palmen ST, Harrison DG, Cobb FR, Morris KG, Harrell FE, Ideker RE, Selvester RH, Wagner GS: A QRS scoring system for assessing left ventricular function after myocardial infarction. N Engl J Med 306, 4-9 (1982)
13. Aldrich HR, Wagner NB, Boswick J, Corsa AT, Jones MG, Grande P, Lee KL, Wagner GS: Use of initial ST-segment deviation for prediction of final electrocardiographic size of acute myocardial infarction. Am J Cardiol 61, 749-753 (1988)
14. Clemmensen P, Grande P, Aldrich HR, Wagner GS: Evaluation of formulas for estimating the final size of acute myocardial infarction from quantitative ST-segment elevation on the initial standard 12-lead ECG. J Electrocardiol 24, 77-83 (1991)
15. TIMI: The Thrombolysis In Acute Myocardial Infarction (TIMI) trial. Phase findings. N Engl J Med 312, 932-936 (1985)
16. Clemmensen P, Ohman M, Sevilla DC, Wagner NB, Quikley PS, Grande P, Wagner GS: Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction Am J Cardiol 70, 1391-1396 (1992)
17. Jeroudi MO, Hartley CJ, Bolli R: Myocardial reperfusion injury: Role of oxygen radicals and potential therapy with antioxidants. Am J Cardiol 73, 2B-7B (1994)
18. Chandra M, Chandra N, Agrawal R, Kumar A, Ghatak A, Pandry VC: The free radical system in ischemic heart disease. Int J Cardiol 43, 121-125 (1994)
19. Cecconi C, Curello S, Cargnoni A, Ferrari R, Albertini A, Visioli O: The role of glutathione status in the protection against ischaemic and reperfusion damase: Effects of N-acetylcysteine. J Moll Cell Cardiol 20, 5-13 (1988)
20. Bassenge E, Stewart DJ: Effects of nitrates in various sections and regions. Nitrates V. Z Kardiol 75(suppl B). Steinkopf Verlag, Darmstadt, 1-7 (1986)
21. Horowitz JD, Henry CA, Syrjanen ML, Louis WJ, Fish RD, Antman EM, Smith TW: Nitroglycerine/N-acetylcysteine in the management of unstable angina pectoris. Eur Heart J 9(suppl A). 95-100 (1988)
22. May DC, Popma JJ, Black WH, Schaefer S, Lee HR, Levine BD, Hillis LD: In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 317, 805-809 (1987)
23. Svendsen JH, Klarlund K, Aldershville J, Waldorff S: N-acetylcysteine modifies the acute effects of isosorbide-5-mononitrate in angina pectoris patients evaluated by exercise testing. J Cardiovasc Pharmacol 13, 320-323 (1989)
24. Boesgaard S, Aldershville J, Poulsen HE, Christensen S, Digepetersen H, Giese J: N-acetylcysteine inhibits angiotensin converting enzyme in vivo. J Pharmacol Exp Therap 265, 1239-1244 (1993)
25. DiPasquale P, Paterna S, Canizzaro S, Bucca V: Does captopril treatment before thrombolysis in acute myocardial infarction attenuate reperfusion damase? Short-term and long-term effects. Int J Cardiol 43, 43-50 (1994)
26. Mayer M, Noble M: N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci 7, 7496-7500 (1994)
27. Steare SE, Yellon DM: The effects of heat stress on cardiac antioxidants(abstr). Eur Heart J 15, 249 (1994)
28. Sochman J, Vrána M, Kolc J: Experimental possibilities to reduce myocardial infarction(abstr).Cas Lék čes 130, 139-143 (1991)